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Review scope
Included studies compared nonpharmacologic interventions involving caregivers (live-in family member) of patients with dementia with control. Studies of respite care, drug therapy, or patients with schizophrenia or bipolar disorder were excluded. Outcomes were neuropsychiatric (behavioral and psychological) dementia symptoms in patients and caregivers' adverse reactions to patients' neuropsychiatric symptoms.
Review methods
MEDLINE, EMBASE/Excerpta Medica, PsycINFO, and Scopus (all 1985 to Jul 2010) were searched for English-language experimental and clinical trials and single-case studies with > 5 patients. 23 studies (n = 3279 patient-caregiver dyads) met the selection criteria: 16 were randomized controlled trials (RCTs), and 7 reported randomization but did not clearly meet the criteria to be classified as RCTs. 14 studies had ≥ 80 caregivers or dyads. Intervention types included skills training for caregivers (18 studies), education for caregivers (21 studies), activity planning and environmental redesign (5 studies), enhancing support for caregivers (5 studies), self-care techniques for caregivers (12 studies), and miscellaneous strategies (e.g., collaborative care with health professionals, exercise for patient) (3 studies), often given in combination; and were delivered individually to caregivers or dyads in 20 studies. Intervention duration ranged from 6 weeks to 24 months.
Main results
Meta-analyses showed that caregiver interventions reduced neuropsychiatric symptoms in patients and reduced related adverse reactions in caregivers (Table) .
Conclusion
Nonpharmacologic interventions involving family caregivers reduce neuropsychiatric symptoms in community-dwelling persons with dementia and caregivers' adverse reactions to neuropsychiatric symptoms. 
Sources

Commentary
As the elderly population expands, dementia will become an increasingly important societal burden, especially given the lack of available efficacious treatments. The behavioral problems that accompany dementia are particularly difficult for families and often lead to the undesirable outcome of institutionalizing patients. Antipsychotics and antidepressants have limited efficacy for controlling the undesirable behavioral symptoms of dementia and are probably harmful (1) . Cholinesterase inhibitors have shown modest efficacy for slowing progression of cognitive decline and for alleviating caregiver perceptions of behavioral disturbance, but the long-term effects have been limited, and it is not known whether they reduce institutionalization (2) . Neuroleptics have black box warnings for increased risk for death.
Nonpharmacologic interventions are appealing options, and the review by Brodaty and Arasaratnam shows that some techniques may be useful for managing behavioral problems. There was substantial heterogeneity among the 23 moderate-quality studies, but the summary effect showed a benefit, albeit small and of questionable long-term impact. Only 6 studies had follow-up beyond 12 months (the longest was 24 mo) and showed reduced institutionalization rates. The studies showed increased tolerance of neuropsychiatric symptoms by caregivers.
The case-management interventions used in the studies require substantial human resources, with frequent phone calls and visits. More research is needed to assess the cost-effectiveness of these resource-intensive interventions. It is also worth questioning whether we are measuring the right outcomes with sufficiently long followup. Caregiver quality of life is often not assessed in these studies.
Unlike pharmacologic therapies, nonpharmacologic interventions have not been shown to be harmful and thus should be the preferred first-line options at this time. With our aging population, finding optimal treatment and management strategies is a public health priority.
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